-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since the beginning of this year, in order to cope with the market environment, the changes of executives of pharmaceutical companies have become more freque.
According to incomplete statistics, from the beginning of January to the end of April 2022, more than 120 senior executives of pharmaceutical companies have changed, including a large number of chairman and general managers of pharmaceutical companies who have resign.
The reasons for resignation are mainly personal reaso.
It is worth noting that in the past week, another group of pharmaceutical companies announced new personnel chang.
On May 18, China Cell announced that it agreed to appoint Xie Liangzhi as the company's general manager, YANG WANG (Wang Yang), Tang Liming, ZHANGHUA LAN (Lan Zhanghua) as the company's deputy general managers, and Zhao Guifen as the company's financial director , Tang Liming concurrently serves as the secretary of the company's board of directors, and the term of office is from the date of deliberation and approval of this board of directors to the date of the expiration of the term of the second board of directo.
Puluo Pharmaceutical also announced on the same day that according to the company's business development needs, the company's board of directors agreed to appoint He Chun as the company's senior deputy general manager after nomination by the company's general manager Xu Xinliang and review by the company's board of directors' nomination committee, and he would no longer serve as the company's deputy general manag.
Manager position; at the same time agreed to appoint Cai Lei as the company's deputy general manag.
On May 17, Janssen announced to employees that Zhu Jingyan, head of the lymphoma business unit of the HIPO business unit, decided to leave Janssen to seek external development opportunities, effective immediate.
At the same time, Janssen appointed Zhang Xianjun, the current head of the patient access and program excellence team of the Government Affairs and Market Access Department, to take over Zhu Jingyan's position and lead the Janssen lymphoma team, effective immediate.
On May 16, Jiangzhong Pharmaceutical announced that the company's board of directors recently received a written resignation report from the company's chairman Lu Xiaoqi.
Lu Xiaoqing resigned from the positions of chairman and director of the company due to organizational transfer, and also resigned from the positions of convener of the strategy committee of the company's board of directors and member of the nomination committ.
On the same day, Harbin Pharmaceutical .
, L.
also announced that due to retirement, .
Xu Haiying resigned as the company's director, member of the strategy and decision-making committee of the board of directors, and general manag.
After resigning, she will no longer hold any positions in the compa.
On May 13, it was reported that .
Bingshi Guo (Taylor), the former CSO of Tianjing Biology, has officially joined NeoX and served as the company's CSO after leaving Tianjing Biology in April 2022, and will lead the company's R&D team in the futu.
Build and consolidate short-term and long-term product pipelines, and provide scientific and strategic guidan.
It is understood that Xingkangyuan neoX was established in 201 It is a bio-tech company that combines artificial intelligence (AI), biophysics, and high-throughput experiments for the research and development of biological macromolecules and multi-specific molecular innovative dru.
The company's business The pipeline mainly focuses on the fields of oncology and immunothera.
It is worth noting that since December 2021, Tianjing Bio has undergone a number of important personnel chang.
On April 28, 2022, Tianjing Bio announced that the company appointed Richard Yeh as Chief Operating Officer (CO.
On April 28, Tianjing Bio also announced the appointment of John Hayslip as Chief Medical Officer (CM.
In 2021, there will be more frequent personnel changes in Tianjing Bio, including the former CEO .
Shen Huaqiong who announced that he will resign due to personal reaso.
The last working day is December 31, 2021; .
Zhu Xiuxuan, an international oncologist, was appointed as the President of Tianjing B.
and directors; appointed senior industry expert .
Long Jiang as chief financial officer (CFO) of Tianjing Biotechnology and joined the company's board of directo.
In general, changes in pharmaceutical executives are closely related to the company's strategy to deal with the market environme.
Under the influence of factors such as centralized procurement and price reduction, industry prospects and performance tasks, many corporate executives have chosen to resign and run away after being measur.
While the current pharmaceutical market reform is still in full swing, the industry expects that with the continuous development of the domestic innovative drug market, talents will become one of the important gaps for various pharmaceutical companies, and the competition for talents in the industry will also intensi.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
According to incomplete statistics, from the beginning of January to the end of April 2022, more than 120 senior executives of pharmaceutical companies have changed, including a large number of chairman and general managers of pharmaceutical companies who have resign.
The reasons for resignation are mainly personal reaso.
It is worth noting that in the past week, another group of pharmaceutical companies announced new personnel chang.
On May 18, China Cell announced that it agreed to appoint Xie Liangzhi as the company's general manager, YANG WANG (Wang Yang), Tang Liming, ZHANGHUA LAN (Lan Zhanghua) as the company's deputy general managers, and Zhao Guifen as the company's financial director , Tang Liming concurrently serves as the secretary of the company's board of directors, and the term of office is from the date of deliberation and approval of this board of directors to the date of the expiration of the term of the second board of directo.
Puluo Pharmaceutical also announced on the same day that according to the company's business development needs, the company's board of directors agreed to appoint He Chun as the company's senior deputy general manager after nomination by the company's general manager Xu Xinliang and review by the company's board of directors' nomination committee, and he would no longer serve as the company's deputy general manag.
Manager position; at the same time agreed to appoint Cai Lei as the company's deputy general manag.
On May 17, Janssen announced to employees that Zhu Jingyan, head of the lymphoma business unit of the HIPO business unit, decided to leave Janssen to seek external development opportunities, effective immediate.
At the same time, Janssen appointed Zhang Xianjun, the current head of the patient access and program excellence team of the Government Affairs and Market Access Department, to take over Zhu Jingyan's position and lead the Janssen lymphoma team, effective immediate.
On May 16, Jiangzhong Pharmaceutical announced that the company's board of directors recently received a written resignation report from the company's chairman Lu Xiaoqi.
Lu Xiaoqing resigned from the positions of chairman and director of the company due to organizational transfer, and also resigned from the positions of convener of the strategy committee of the company's board of directors and member of the nomination committ.
On the same day, Harbin Pharmaceutical .
, L.
also announced that due to retirement, .
Xu Haiying resigned as the company's director, member of the strategy and decision-making committee of the board of directors, and general manag.
After resigning, she will no longer hold any positions in the compa.
On May 13, it was reported that .
Bingshi Guo (Taylor), the former CSO of Tianjing Biology, has officially joined NeoX and served as the company's CSO after leaving Tianjing Biology in April 2022, and will lead the company's R&D team in the futu.
Build and consolidate short-term and long-term product pipelines, and provide scientific and strategic guidan.
It is understood that Xingkangyuan neoX was established in 201 It is a bio-tech company that combines artificial intelligence (AI), biophysics, and high-throughput experiments for the research and development of biological macromolecules and multi-specific molecular innovative dru.
The company's business The pipeline mainly focuses on the fields of oncology and immunothera.
It is worth noting that since December 2021, Tianjing Bio has undergone a number of important personnel chang.
On April 28, 2022, Tianjing Bio announced that the company appointed Richard Yeh as Chief Operating Officer (CO.
On April 28, Tianjing Bio also announced the appointment of John Hayslip as Chief Medical Officer (CM.
In 2021, there will be more frequent personnel changes in Tianjing Bio, including the former CEO .
Shen Huaqiong who announced that he will resign due to personal reaso.
The last working day is December 31, 2021; .
Zhu Xiuxuan, an international oncologist, was appointed as the President of Tianjing B.
and directors; appointed senior industry expert .
Long Jiang as chief financial officer (CFO) of Tianjing Biotechnology and joined the company's board of directo.
In general, changes in pharmaceutical executives are closely related to the company's strategy to deal with the market environme.
Under the influence of factors such as centralized procurement and price reduction, industry prospects and performance tasks, many corporate executives have chosen to resign and run away after being measur.
While the current pharmaceutical market reform is still in full swing, the industry expects that with the continuous development of the domestic innovative drug market, talents will become one of the important gaps for various pharmaceutical companies, and the competition for talents in the industry will also intensi.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
